BIOMIRA'S TRUQUANT BR CA 15-3 RIA IS APPROVABLE IF FIRM ALTERS LABELING AND PROVIDES EXPLANATORY INFORMATION ON FALSE POSITIVES, PANEL SAYS
This article was originally published in The Gray Sheet
Executive Summary
Labeling for Biomira's Truquant BR CA 15-3 radioimmunoassay needs to be modified to reflect the limitations of the test before FDA clears the company's premarket approval application, the agency's Immunology Devices Advisory Panel concluded at a Sept. 21 meeting in Gaithersburg, Maryland.
You may also be interested in...
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.